Last reviewed · How we verify
NCT04251247
Diagnostic Value of D-dimer/Fibrinogen Ratio in Patients With Acute Aortic Dissection
trial testing D-dimer/fibrinogen ratio in Aortic Dissection in 159 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Dr. Lutfi Kirdar Kartal Training and Research Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 159 |
| Start date | 1 March 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 2 locations across Turkey (Türkiye) |
Drugs / interventions tested
- D-dimer/fibrinogen ratio
Conditions studied
- Aortic Dissection — all drugs for Aortic Dissection →
- Pulmonary Embolism — all drugs for Pulmonary Embolism →
Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Who can join
18 and older, any sex, with Aortic Dissection or Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute aortic dissection is rare but potentially life-threatening disease with an incidence of 5-30 cases per million, annually. Therefore prompt diagnosis is crucial. D-dimer values have been shown to be useful in the diagnosis of acute aortic dissection. Fibrinogen levels have been shown to be low, normal or high in individuals with acute aortic dissection. This study aims to investigate whether D-dimer/fibrinogen ratio can be valuable for diagnosis of acute aortic dissection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04251247
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Dissection
Currently open trials in the same condition.
- NCT06550986 — False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study · NA · recruiting
- NCT06968806 — Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection · Phase 3 · recruiting
- NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
- NCT06915545 — Study on the Aortic Arch Single Branch Stent Graft System · NA · recruiting
- NCT07117825 — Aortic Dissection fAlse enlarGement radIomics predictiOn · active not recruiting
Other Dr. Lutfi Kirdar Kartal Training and Research Hospital trials
Trials by the same sponsor.
- NCT07322497 — Comparison of Video Based Phone App vs. Supervised Preoperative Exercise for ACL Reconstruction · NA · not yet recruiting
- NCT07141966 — Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophren · completed
- NCT07142018 — Investigation of the Effect of Hyperbaric Oxygen Therapy in Patients With Avascular Necrosis · active not recruiting
- NCT07144553 — Relationship Between Eating Disorders, Anthropometric Characteristics, and Physical Activity After Bariatric Surgery · completed
- NCT07140042 — Physical Fitness, Physical Activity Level, Depression and Quality of Life in Bipolar and Schizophrenia Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04251247 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Lutfi Kirdar Kartal Training and Research Hospital
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04251247.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing